| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
| ln Vitro |
In rats, 5-HT-induced fundus strip contraction is 46% inhibited by cinromide (10-100 μM). Monoamine oxidase produced from rat liver and brain is inhibited by cinromide (100 μM) [3].
|
|---|---|
| ln Vivo |
In mice, cinromide causes electroconvulsions and pentetrazo1-induced convulsions, with ED50 values of 60±11 mg/kg, 90±15 mg/kg, and 80±15 mg/kg, 300± 61 mg/kg, correspondingly. After being administered intraperitoneally to rats, cinromide exhibited dose-related action against tepstatazol, with an ED50 of 58 ± 11 mg/kg. Moreover, in an intravenous leptamazole threshold test in rats, cinromide (75 mg/kg) markedly raised the leptamazole concentration needed to cause clonic seizures. Cinromide (300 mg/kg, i.p.) did not significantly affect dogs who were sedated and left with their chests open four hours after treatment, nor did it significantly affect dogs that were awake five hours after oral dose of 300 and 600 mg/kg. cinromide [1]. Neuronal responses to unconditioned maxillary nerve stimulation are inhibited by cinromide (40 mg/kg, IV), which increases latency and decreases spike counts. Segmental inhibition and the latency of unconditioned responses are both dose-dependently increased by cinromide (20, 40, 80 mg/kg, iv). Electroencephalogram and periventricular inhibition are reduced by sinromid [4].
|
| References |
[1]. Chiu P, et al. The effect of cinromide on "kindled" seizures in the rat. Neuropharmacology. 1982;21(3):273-276.
[2]. Yadav A, et al. Novel Chemical Scaffolds to Inhibit the Neutral Amino Acid Transporter B0AT1 (SLC6A19), a Potential Target to Treat Metabolic Diseases. Front Pharmacol. 2020;11:140. Published 2020 Feb 28. [3]. Soroko FE, et al. Cinromide (3-bromo-N-ethylcinnanamide), novel anticonvulsant agent. J Pharm Pharmacol. 1981 Nov;33(11):741-3. [4]. Fromm GH, et al. Effect of cinromide on inhibitory and excitatory mechanisms. Epilepsia. 1983 Aug;24(4):394-400 |
| Additional Infomation |
Cinromide is a member of cinnamamides and a secondary carboxamide.
|
| Molecular Formula |
C11H12BRNO
|
|---|---|
| Molecular Weight |
254.127
|
| Exact Mass |
253.01
|
| CAS # |
58473-74-8
|
| PubChem CID |
688145
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.369g/cm3
|
| Boiling Point |
417.5ºC at 760mmHg
|
| Melting Point |
89-91ºC(lit.)
|
| Flash Point |
206.3ºC
|
| Index of Refraction |
1.591
|
| LogP |
2.989
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
14
|
| Complexity |
215
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
BrC1=C([H])C([H])=C([H])C(=C1[H])/C(/[H])=C(\[H])/C(N([H])C([H])([H])C([H])([H])[H])=O
|
| InChi Key |
LDCXGZCEMNMWIL-VOTSOKGWSA-N
|
| InChi Code |
InChI=1S/C11H12BrNO/c1-2-13-11(14)7-6-9-4-3-5-10(12)8-9/h3-8H,2H2,1H3,(H,13,14)/b7-6+
|
| Chemical Name |
(E)-3-(3-bromophenyl)-N-ethylprop-2-enamide
|
| Synonyms |
Vumide; Cinromide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~983.79 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (8.19 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (8.19 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (8.19 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.9350 mL | 19.6750 mL | 39.3499 mL | |
| 5 mM | 0.7870 mL | 3.9350 mL | 7.8700 mL | |
| 10 mM | 0.3935 mL | 1.9675 mL | 3.9350 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
